THE WHAT? Johnson & Johnson (J&J) has reported 2021 Q4 sales of US$24.8 billion, a growth of 10.4 percent, with full year 2021 sales reaching US$93.8 billion, up 13.6 percent.
THE DETAILS J&J’s Consumer Health arm saw a reported Q4 rise of 1.1 percent and a full year growth of 4.1 percent.
This was primarily driven by OTC products such as Tylenol analgesics and digestive health. As well as Neutrogena and Aveeno products in skin health and beauty, whose growth was attributed to COVID-19 market recovery.
Regionally, the U.S. saw a 3 percent reported rise in Q4, while International rose 18.5 percent and Worldwide grew 10.4 percent.
THE WHY? Joaquin Duato, Chief Executive Officer, said, “Our 2021 performance reflects continued strength across all segments of our business. Guided by Our Credo, I am honored to assume the role of CEO, leading our global teams in continuing our work to deliver life-changing solutions to consumers, patients, and health care providers.
“Given our strong results, financial profile, and innovative pipeline we are well positioned for success in 2022 and beyond.”